Results 201 to 210 of about 253,625 (250)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer [PDF]

European Journal of Nuclear Medicine and Molecular Imaging, 2017
is the first targeted alpha therapy for patients with castration resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach.
Ignasi Carrio, Giuseppe De Vincentis, Stefano Fanti   +2 more
exaly   +2 more sources

Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review

Critical Reviews in Oncology/Hematology, 2020
Chemotherapeutic agents (docetaxel, cabazitaxel), hormonal therapies (abiraterone, enzalutamide) and radium- 223 improve survival in patients with bone metastatic castration-resistant prostate cancer (mCRPC).
Maria Concetta Cursano, M Iuliani, Chiara Casadei   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Radium-223 chloride

Reactions Weekly, 2019
  +9 more sources

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial.

Annals of Oncology
BACKGROUND The EORTC 1333 'PEACE-3' study investigated the combination of enzalutamide and 6 monthly injections of radium-223 (Ra223) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases.
B. Tombal, A. Choudhury, F. Saad, E. Gallardo, A. Soares, Y. Loriot, R. McDermott, A. Rodríguez-Vida, P. Isaacsson Velho, F. Nolè, F. Cruz, T. Roumeguere, G. Daugaard, R. Yamamura, E. Bompas, P. Maroto, F. Gomez Veiga, I. Skoneczna, K. Martins da Trindade, F. Mavignier Carcano, F. Lecouvet, C. Coens, C. Poncet, B. Fournier, S. Gillessen   +24 more
semanticscholar   +1 more source

Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis.

European Urology
Bone health is central to the management of patients with metastatic castration-resistant prostate cancer (mCRPC). International guidelines recommend giving a bone-protecting agent (BPA) to patients with mCRPC and bone metastases.
S. Gillessen, Bertrand F. Tombal, F. Turco, Ananya Choudhury, A. Rodríguez-Vida, E. Gallardo, P. I. Velho, Franco Nolè, F. Cruz, Y. Loriot, Ray McDermott, T. Roumeguere, G. Daugaard, R. Yamamura, E. Bompas, P. Maroto, M. H. Polo, K. M. da Trindade, D. Preto, I. Skoneczna, F. Lecouvet, C. Coens, B. Fournier, Fred Saad   +23 more
semanticscholar   +1 more source

A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.

Journal of Clinical Oncology
5007 Background: Radium-223 is an α-emitting radioisotope which has improved overall survival (OS) in men with CRPC with BM. PARP inhibitors demonstrate synergy with radiation.
R. Mckay, W. Xie, Archana Ajmera, Christina Jamieson, Arlene Araneta, E. Folefac, Arif Hussain, C. Kyriakopoulos, Adam Olson, M. Parikh, R. Parikh, B. Saraiya, L. Pasquina, Sarah Clifford, Merrida A. Childress, A. Gasco Hernandez, S. Ivy, E. V. Van Allen, B. Kochupurakkal, G. Shapiro   +19 more
semanticscholar   +1 more source

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.

European Urology Oncology, 2023
BACKGROUND Radium-223 is an active therapy option for bone metastatic castration-resistant prostate cancer (mCRPC). The lack of adequate biomarkers for patient selection and response assessment are major drawbacks for its use.
N. Romero-Laorden, D. Lorente, G. de Velasco, R. Lozano, B. Herrera, J. Puente, P. P. López, A. Medina, E. Almagro, E. González-Billalabeitia, Jose Carlos Villla-Guzman, A. González-del-Alba, P. Borrega, N. Laínez, Ana Fernández-Freire, Amaia Hernández, A. Rodríguez-Vida, I. Chirivella, E. Fernández-Parra, F. López-Campos, Maria Isabel Pacheco, R. Morales-Barrera, O. Fernández, R. Villatoro, R. Luque, Susana Hernando, Daniel Castellano, Elena Castro, David Olmos   +28 more
semanticscholar   +1 more source

A New ERA for radium-223? Optimizing Treatment by Balancing Efficacy and Toxicity Through Combination Therapies.

Critical reviews in oncology/hematology
The pronounced bone tropism of prostate cancer (PCa) has prompted the development of therapies that specifically act in areas of increased bone deposition and selectively exert anti-tumor effects in osteoblastic metastases.
G. Farinea, Luca Cozzone, Simona Butticè, Andrea Mogavero, R. F. Di Stefano, Tiziana Angusti, A. Parente, M. Tucci, C. Buttigliero   +8 more
semanticscholar   +1 more source

Utilization Patterns and Survival in Older Men With Metastatic Prostate Cancer Treated with Radium-223 in the United States: A SEER-Medicare Study.

Clinical Genitourinary Cancer
INTRODUCTION Previous research on Radium-223 treatment patterns in metastatic prostate cancer has been limited to select sites, oncology practices, or claims databases.
Bo Zhou, Amit D. Raval, Yifan Zhang, N. Sambamoorthi, Matthew J. Korn, N. Constantinovici, R. McKay, U. Sambamoorthi   +7 more
semanticscholar   +1 more source

Radium-223-chloride

Reactions Weekly, 2017
  +8 more sources